Funder
U.S. Department of Health & Human Services | National Institutes of Health
UC | UCLA | Jonsson Comprehensive Cancer Center
Cancer Research Institute
Alliance for Cancer Gene Therapy
Publisher
Springer Science and Business Media LLC
Reference75 articles.
1. Ho, P. & Chen, Y. Y. Synthetic biology in immunotherapy and stem cell therapy engineering. in Synthetic Biology (eds Smolke, C. et al.) 349–372 (Wiley-VCH, 2018); https://doi.org/10.1002/9783527688104.ch17
2. Brudno, J. N. et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267–2280 (2018).
3. Cohen, A. D. et al. Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood 130, 505 (2017).
4. Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341–1355 (2019).
5. Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献